Clinical Trials Program

Partnering_BG1

Clinical Trials


Iceni™ Pharmaceuticals is currently organising a Phase IIa safety/efficacy trial with Cilcane®, aimed at newly diagnosed patients who will be treated with a standard induction regime of bortezomib, thalidomide and dexamethasone. Iceni™ aims to begin patient recruitment later in 2017 following finalisation of clinical trial sites.

Get in touch to be kept up to date with our clinical development program.

Your Name (required)

Your Email (required)

Subject

Your Message

Loading